BR112021019054A2 - Formas sólidas de um composto do modificador alostérico da proteína do núcleo do vhb - Google Patents
Formas sólidas de um composto do modificador alostérico da proteína do núcleo do vhbInfo
- Publication number
- BR112021019054A2 BR112021019054A2 BR112021019054A BR112021019054A BR112021019054A2 BR 112021019054 A2 BR112021019054 A2 BR 112021019054A2 BR 112021019054 A BR112021019054 A BR 112021019054A BR 112021019054 A BR112021019054 A BR 112021019054A BR 112021019054 A2 BR112021019054 A2 BR 112021019054A2
- Authority
- BR
- Brazil
- Prior art keywords
- solid forms
- hbv
- core protein
- allosteric modifier
- hbv core
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 230000003281 allosteric effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003607 modifier Substances 0.000 title abstract 3
- 101710132601 Capsid protein Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- YLJBFYZGSKMBEZ-MBSDFSHPSA-N C(C)OC(=O)C=1[C@@H](N=C(NC1CN1C[C@@H]2N(CC1)C(N(C2)CC(C(=O)O)(C)C)=O)C=2SC=CN2)C2=C(C(=CC=C2)F)C Chemical compound C(C)OC(=O)C=1[C@@H](N=C(NC1CN1C[C@@H]2N(CC1)C(N(C2)CC(C(=O)O)(C)C)=O)C=2SC=CN2)C2=C(C(=CC=C2)F)C YLJBFYZGSKMBEZ-MBSDFSHPSA-N 0.000 abstract 1
- 102000007999 Nuclear Proteins Human genes 0.000 abstract 1
- 108010089610 Nuclear Proteins Proteins 0.000 abstract 1
- 229940124765 capsid inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
formas sólidas de um composto do modificador alostérico da proteína do núcleo do vhb. a presente invenção refere-se a novas formas sólidas de composto (i), 3-[(8as)-7-[[(4s)-5-etoxicarbonil-4-(3-fluoro-2-metil-fenil)-2-tiazol-2-il-1,4-di-hidropirimidin-6-il] metil]-3-oxo-5,6,8,8a-tetra-hidro-1h-imidazo[1,5-a]pirazin-2-il]-2,2-dimetil-ácido propanoico e composições farmacêuticas compreendendo formas sólidas dos mesmos divulgado neste documento, que pode ser usado como um inibidor de capsídeo de vhb (ou modificador alostérico de proteína nuclear de vhb) ou para o tratamento ou profilaxia de uma doença viral em um paciente relacionada à infecção por vhb ou uma doença causada por infecção por vhb.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019079543 | 2019-03-25 | ||
PCT/EP2020/057937 WO2020193459A1 (en) | 2019-03-25 | 2020-03-23 | Solid forms of a compound of hbv core protein allosteric modifier |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021019054A2 true BR112021019054A2 (pt) | 2021-11-30 |
Family
ID=70005624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021019054A BR112021019054A2 (pt) | 2019-03-25 | 2020-03-23 | Formas sólidas de um composto do modificador alostérico da proteína do núcleo do vhb |
Country Status (12)
Country | Link |
---|---|
US (2) | US11873302B2 (pt) |
EP (1) | EP3947383A1 (pt) |
JP (1) | JP2022525522A (pt) |
KR (1) | KR20210136078A (pt) |
CN (1) | CN113614088A (pt) |
AU (1) | AU2020249331A1 (pt) |
BR (1) | BR112021019054A2 (pt) |
CA (1) | CA3130596A1 (pt) |
IL (1) | IL286599A (pt) |
MX (1) | MX2021011614A (pt) |
TW (1) | TW202102503A (pt) |
WO (1) | WO2020193459A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3114128T (lt) * | 2014-03-07 | 2019-03-25 | F. Hoffmann-La Roche Ag | Nauji 6 padėtyje kondensuoti heteroarildihidropirimidinai, skirti hepatito b virusinės infekcijos gydymui ir profilaktikai |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
DE10012823A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
DE10013126A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
DE10125131A1 (de) | 2001-05-23 | 2002-12-05 | Bayer Ag | Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats |
WO2005085462A1 (en) | 2004-02-27 | 2005-09-15 | Dsm Ip Assets B.V. | Enzymatic preparation of an enantiomerically enriched beta-2-amino acids |
WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
BRPI0616378A2 (pt) | 2005-09-22 | 2011-06-21 | Scripps Research Inst | inibidores de proteìna cinase baseados em alcóxi indolinona e métodos para modulação da atividade catalìtica |
GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
CN100453542C (zh) | 2007-04-30 | 2009-01-21 | 广东东阳光药业有限公司 | 2-杂环取代的二氢嘧啶消旋化合物的拆分方法 |
WO2009067547A1 (en) | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
ES2454366T3 (es) | 2008-02-22 | 2014-04-10 | Neurotune Ag | Compuestos bicíclicos que contienen nitrógeno activos en afecciones de dolor crónico |
CN103536906A (zh) | 2008-06-05 | 2014-01-29 | 津莫吉尼蒂克斯公司 | 利用聚乙二醇化的iii 型干扰素治疗丙型肝炎 |
CA2735177C (en) | 2008-08-29 | 2014-03-25 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Saturated bicyclic heterocyclic derivatives as smo antagonists |
WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
TWI668217B (zh) | 2012-08-24 | 2019-08-11 | 廣東東陽光藥業有限公司 | 二氫嘧啶類化合物及其在藥物中的應用 |
WO2014037480A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
EA201592126A1 (ru) | 2013-05-17 | 2016-05-31 | Ф. Хоффманн-Ля Рош Аг | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b |
CN104650069B (zh) | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
LT3114128T (lt) | 2014-03-07 | 2019-03-25 | F. Hoffmann-La Roche Ag | Nauji 6 padėtyje kondensuoti heteroarildihidropirimidinai, skirti hepatito b virusinės infekcijos gydymui ir profilaktikai |
AR101319A1 (es) | 2014-07-31 | 2016-12-07 | Hoffmann La Roche | Resolución quiral de los ésteres del ácido 4-aril-2-tiazol-2-il-1,4-dihidropirimidin-5-carboxílico |
WO2016102438A1 (en) | 2014-12-23 | 2016-06-30 | F. Hoffmann-La Roche Ag | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues |
MY190603A (en) * | 2015-03-16 | 2022-04-27 | Hoffmann La Roche | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
AU2016349685A1 (en) | 2015-11-03 | 2018-03-15 | F. Hoffmann-La Roche Ag | Combination therapy of an HBV capsid assembly inhibitor and an interferon |
WO2017108630A1 (en) * | 2015-12-21 | 2017-06-29 | F. Hoffmann-La Roche Ag | Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor |
AR107633A1 (es) * | 2016-02-19 | 2018-05-16 | Hoffmann La Roche | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico |
CN109689059A (zh) | 2016-08-24 | 2019-04-26 | 豪夫迈·罗氏有限公司 | Hbv衣壳组装抑制剂和核苷或核苷酸类似物的组合疗法 |
ES2894605T3 (es) | 2016-09-13 | 2022-02-15 | Hoffmann La Roche | Tratamiento combinado con un agonista de TLR7 y un inhibidor del ensamblaje de la cápside del VHB |
EP3634431A4 (en) | 2017-05-31 | 2021-06-23 | Arbutus Biopharma Corporation | THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT FOR HEPATITIS B |
EP3700573A1 (en) | 2017-10-24 | 2020-09-02 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
EP3980419A1 (en) | 2019-06-06 | 2022-04-13 | F. Hoffmann-La Roche AG | Alternative process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid |
JP2022548652A (ja) | 2019-09-20 | 2022-11-21 | エフ.ホフマン-ラ ロシュ アーゲー | コアタンパク質アロステリックモジュレータを使用してhbv感染を処置する方法 |
-
2020
- 2020-03-23 BR BR112021019054A patent/BR112021019054A2/pt unknown
- 2020-03-23 EP EP20710759.0A patent/EP3947383A1/en active Pending
- 2020-03-23 WO PCT/EP2020/057937 patent/WO2020193459A1/en unknown
- 2020-03-23 MX MX2021011614A patent/MX2021011614A/es unknown
- 2020-03-23 CA CA3130596A patent/CA3130596A1/en active Pending
- 2020-03-23 JP JP2021556217A patent/JP2022525522A/ja active Pending
- 2020-03-23 KR KR1020217032073A patent/KR20210136078A/ko not_active Application Discontinuation
- 2020-03-23 CN CN202080023475.6A patent/CN113614088A/zh active Pending
- 2020-03-23 AU AU2020249331A patent/AU2020249331A1/en active Pending
- 2020-03-24 TW TW109109858A patent/TW202102503A/zh unknown
- 2020-03-24 US US16/828,408 patent/US11873302B2/en active Active
-
2021
- 2021-09-22 IL IL286599A patent/IL286599A/en unknown
-
2023
- 2023-12-14 US US18/539,773 patent/US20240116941A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200308178A1 (en) | 2020-10-01 |
US11873302B2 (en) | 2024-01-16 |
MX2021011614A (es) | 2021-10-13 |
EP3947383A1 (en) | 2022-02-09 |
AU2020249331A1 (en) | 2021-09-23 |
JP2022525522A (ja) | 2022-05-17 |
WO2020193459A1 (en) | 2020-10-01 |
IL286599A (en) | 2021-10-31 |
TW202102503A (zh) | 2021-01-16 |
CN113614088A (zh) | 2021-11-05 |
CA3130596A1 (en) | 2020-10-01 |
US20240116941A1 (en) | 2024-04-11 |
KR20210136078A (ko) | 2021-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
BR112023016299A2 (pt) | Composições e métodos para inibir kras | |
BR112018071216A2 (pt) | inibidores de bromodomínios | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
ECSP12011944A (es) | Ácidos carboxílicos macrocíclicos y acilsulfonamidas como inhibidores de replicación del hcv | |
BRPI0507609A (pt) | combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina | |
BR112022026321A2 (pt) | Análogos de 1'-ciano nucleosídeo e usos dos mesmos | |
BR112012018529A2 (pt) | inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna | |
EA201270666A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
EA201001532A1 (ru) | Соединения фенилзамещенного 2-имино-3-метилпирролопиримидинона в качестве ингибиторов bace-1, композиции и их применение | |
EA200971026A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
BR112014030424A8 (pt) | Formas cristalinas de um inibidor de quinase de tirosina de bruton | |
EA200602130A1 (ru) | Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов | |
Enkhtaivan et al. | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase | |
EA200702384A1 (ru) | Лечение заболеваний печени, в патогенезе которых задействовано железо | |
BR112015019754A2 (pt) | derivados de 2-((4-amino-3-(3-fluoro-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)metil)-3-(2-(trifluoro-metil)bezil)quinazolin-4(3h)-ona e seu uso como inibidores de fosfoinositídeo 3-quinase | |
BR112014012628A2 (pt) | di-hidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp | |
BR112013006030A2 (pt) | composto e sais, solvatos, n-óxidos ou prodrogas farmaceuticamente aceitáveis, composição farmacêutica, uso do composto, kit, método de tratamento de uma doença, e, composição anti-helmíntica | |
BR112012017705A2 (pt) | derivados de sulfonamidas de 3,4-diarilpirazóis como inibidores da proteína cinase | |
BRPI0922806B8 (pt) | composição farmacêutica oral compreendendo bendamustina | |
BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
BR112018072468A2 (pt) | composto para uso como um inibidor de quinase, composto ou n-óxido, sal farmaceuticamente aceitável, solvato farmaceuticamente aceitável ou estereoisômero, método in vitro para inibir atividade de proteína quinase e composição farmacêutica | |
BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
BRPI0514724A (pt) | inibidores da enzima hiv integrase |